ELI LILLY WKN: 858560 ISIN: US5324571083 Kürzel: LLY Forum: Aktien Thema: Hauptdiskussion

Lass mal wirken 😉

unglaublich tolle zahlen in allen bereichen🚀🚀inkl ausblick

kgv ca 24 billig

ELI LILLY $LLY Q2’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $23.0B (Est. $20.7B) 🟢; +48% YoY 🔹 Adj. EPS: $8.38 (Est. $6) 🟢; +33% YoY 🔹 Mounjaro: $9.9B; +91% YoY 🔹 Zepbound: $4.9B (Est. $4.6B) 🟢; +44% YoY 🔹 GM: 85.8%; +1.5pts YoY FY26 Guide: 🔹 EPS: $35.50-$36.50 (Est. $34.20) 🟢 🔹 Revenue: $85B-$87B (Est. $85.45B) 🟡 🔹 Performance Margin: 49.0%-50.5% 🔹 Tax Rate: unchanged Other Q2 Metrics: 🔹 Operating Income: $9.0B (Est. $7.28B) 🟢; +31% YoY 🔹 Net Income: $7.1B (Est. $5.42B) 🟢; +25% YoY 🔹 Key Products Revenue: $15.7B 🔸 Acquired IPR&D charges: $2.8B; Q2 EPS included a $3.03 charge Comments: 🔸 “Lilly's momentum continues, as we delivered 48% revenue growth and raised our full-year guidance” 🔸 “With our next-generation weight-loss medicine retatrutide and its complete clinical data package in hand, new manufacturing capacity coming online, and exciting new assets entering our pipeline through business development”

$LLY Q2 EARNINGS DOUBLE BEAT + RAISE 🔥 Adj. EPS: $8.38 vs $6.01 est Sales: $22.974B vs $20.725B est Raised FY2026 Sales Guidance

DOUBLEEEE BEAAATIN

Beat 🤝

🚀🚀🚀🚀

Was jetzt??

🚀

Schaut vorbörslich zumindest nicht schlecht aus; die Zahlen sollten um 12.45 kommen..

nicht der anleger sondern der nichts nutzen analysten die ihre erwartungen immer zu hoch angeben.

Das kommt darauf an, wie hoch die Erwartungen der Anleger sind...

morgen top zahlen und neues ath bald